UKRI's new strategy (2026 - 2031)

The headline: life sciences gets £1.5bn, but health tech is scattered across multiple buckets

The life sciences Priority Programme receives £1.5 billion, with explicitly named priorities including data-enabled diagnostics, next-generation medicines and medtech, and innovations that support the NHS shift from hospital to community care. That hospital-to-community framing is significant — it directly signals where product-market fit will be rewarded with public funding and NHS procurement interest.

But healthtech is not confined to the life sciences bucket. The digital and technologies programme (£4 billion) prioritises AI across six areas including accelerating innovation for economic growth and societal benefit, and responsible and trustworthy AI - with total AI investment across the Spending Review period exceeding £1.6 billion. Any health AI product sits at the intersection of both programmes, which creates both opportunity and navigational complexity for SMEs.

Useful information for Bidshaper's clients

Grant opportunity is significant but selective. UKRI will establish a Velocity concierge approach to commercialisation, offering an end-to-end innovation service from early-stage research to scale-up finance and regulatory support, targeting businesses with the greatest scope for transformation and national benefit. Tthis is explicitly not a broad-based grants programme, UKRI is being more selective, doing fewer things better. The bar for bid quality and strategic fit goes up.

The procurement angle. UKRI identifies removing friction in procurement and tech transfer as one of its three levers for accelerating businesses to scale. This is relevant for Bidshaper clients pursuing Contracts for Innovation and similar instruments - if UKRI delivers on this, the procurement pathway for health SMEs should become less opaque.

The leverage ratio matters. UKRI is targeting an average of £3 of private investment for every £1 of public funding across Priority Programme investments. Bid narratives that cannot demonstrate a credible path to private co-investment will be disadvantaged.

Specific funding instruments to watch

Velocity

Velocity is described as a concierge approach to fast-tracking commercialisation of innovation, helping companies turn promising technology into scalable growth, with UKRI stepping in at critical moments and providing tailored support over time. This is the highest-touch support on offer. Health and care SMEs with a credible commercial track record and a technology that maps to a named Priority Programme should be positioning for this actively. The entry criteria matter, Bidshaper will help its clients to know whether they qualify before the programme launches.

Proof of Concept and Impact Acceleration

UKRI is consolidating its translation investments into four schemes: Prosperity Partnerships for collaborative R&I, Impact Acceleration to test applicability of new ideas to commercial application, Proof of Concept funding to test ideas at scale, and Entrepreneurship training support.

The R&D Missions Accelerator (£500 million)

The Missions Accelerator is designed to tackle key research problems facing the government's five national missions, with clear measurable targets and specific deadlines; and projects not delivering are expected to stop early. Health is a near-certain mission area. Bidshaper clients with solutions that map to NHS productivity, early diagnosis, or community care will have a strong narrative fit here. The "stop early" clause is unusual and signals that UKRI wants credible delivery plans, not aspirational ones.

Local Innovation Partnerships Fund (£500 million)

The LIPF brings together civic institutions, businesses and universities to co-create projects that build on regional R&I strengths, with Wave 2 just launched (July 2026). Health and care SMEs with existing university or NHS trust relationships in named cluster regions (Manchester, West Midlands, Belfast, Glasgow) should be exploring consortium bids. This is a vehicle for Bidshaper clients who cannot lead a national bid but can anchor a regional one.

Processing times are improving - but only for well-prepared applicants

UKRI is committing to cut median application-to-decision times from 195 days to 90 days for applicant-mode funding, and from 127 days to 60 days for targeted mode, by 2031 - with interim reductions expected from 2026 to 2027.

Faster decisions reduce the cash flow risk of grant dependency for SMEs. But faster processing also means less tolerance for weak applications that clog the system. The quality bar goes up as the timeline compresses.

The four schemes UKRI is consolidating its translation funding into:

Prosperity Partnerships

• Collaborative R&I between businesses and research organisations

• Designed for longer-term, structured partnerships rather than one-off projects

• The entry point for clients who want to work with a university or NHS trust on joint research with a commercial endpoint

• Best suited to Bidshaper clients with an existing academic relationship they want to formalise and fund

Impact Acceleration

• Tests whether a new idea or technology has practical commercial application

• Earlier stage than Proof of Concept - this is about establishing feasibility in a real-world context

• Likely the right entry point for Bidshaper clients who have something promising but have not yet demonstrated it works outside a lab or pilot setting

• Often delivered through university Impact Acceleration Accounts, so the university is typically the lead applicant

Proof of Concept

• Tests a validated idea at scale

• Comes after Impact Acceleration - the technology works in principle and this funding proves it works at volume or in a full deployment context

• The critical step before commercialisation and the one most relevant to Bidshaper clients approaching NHS procurement conversations

• Requires a credible scale-up plan and, given the new leverage requirement, likely some evidence of investor interest

Entrepreneurship Training Support

• The softer end of the portfolio; skills and capability development rather than direct R&D funding

• Relevant for founder-led SMEs where the limiting factor is business and commercialisation skills rather than the technology itself

• Less likely to be the primary route for established Bidshaper clients, but worth knowing for earlier-stage companies in your pipeline

The practical sequencing for most health and care SME clients would be:

Impact Acceleration → Proof of Concept → Velocity (the concierge commercialisation support) → private investment leverage.